Alpha-Ketoglutarate (AKG) for Healthy Aging: What the Human Evidence Can and Cannot Show

Bottom line: Alpha-ketoglutarate has an impressive metabolic résumé and a lot of longevity marketing, but the direct human anti-aging case is still weak. The most famous human result used an uncontrolled multi-ingredient product, the best modern randomized program has not yet supplied an efficacy result here, and newer observational data still cannot tell us whether AKG itself caused a younger biological-age signal.

What AKG is

Alpha-ketoglutarate, usually shortened to AKG, is a normal intermediate in the tricarboxylic-acid cycle. It also participates in nitrogen metabolism and serves as a co-substrate for multiple enzymes involved in cell signaling and epigenetic regulation.

That makes AKG biologically interesting before anyone puts it in a capsule.

Animal and mechanistic research helped push AKG into the longevity space. The harder question is whether supplementing humans produces meaningful aging-related benefits.

The 2022 human-evidence review was cautious

A 2022 review in Trends in Endocrinology & Metabolism summarized the rationale for AKG supplementation and the available human literature.[1]

The authors noted older human studies in areas such as recovery, wound healing, and muscle-related outcomes, but concluded that contemporary evidence had not established AKG as a treatment for aging or age-related disease.[1]

That distinction still matters. A molecule can be central to metabolism and extend lifespan in model organisms without producing the same outcome when taken as a human supplement.

What about the famous "8 years younger" result?

The headline comes from a 2021 retrospective analysis of 42 people who used a commercial formulation called Rejuvant for an average of about seven months.[2]

The product contained calcium alpha-ketoglutarate plus vitamins, and the study compared DNA-methylation age before and after use. The investigators reported an average reduction of roughly eight years in the methylation-age estimate.[2]

There was no randomized placebo group. Participants knew they were taking the product. The formulation contained multiple ingredients. Lifestyle changes could not be fully separated from supplementation. And the outcome was a biological-age algorithm—not a direct measure of disability, disease incidence, or lifespan.

The ABLE randomized trial is the study to watch

The ABLE program was designed as a double-blind placebo-controlled randomized trial of 1 g sustained-release calcium-AKG daily for six months in 120 generally healthy adults aged 40 to 60 whose DNA-methylation age exceeded chronological age.[3]

Its planned primary outcome is change in DNA-methylation age. Secondary measures include inflammatory and metabolic markers, strength, arterial stiffness, skin autofluorescence, and aerobic capacity.[3]

A 2025 paper reported successful recruitment of the planned 120 participants and evaluated the feasibility of this biologically selected enrollment strategy.[4]

That is trial progress, not an efficacy result. A recruitment paper cannot be cited as evidence that calcium-AKG reduced biological age or improved function.

Why a methylation clock is not the same as reversing aging

Epigenetic clocks can be useful research tools. They summarize patterns in DNA methylation that correlate with chronological age and, depending on the clock, some health outcomes.

But changing a clock score does not automatically mean an intervention reversed the underlying aging process by the same number of years.

Different clocks can respond differently, and it is still necessary to show that a clock change translates into better clinical outcomes.

The newer 2026 cohort adds a signal, not proof

A 2026 study analyzed a cohort of unusually health-conscious people who had saliva-based epigenetic testing and reported their supplement use.[5]

A delayed-release calcium-AKG plus vitamin product was associated with a lower biological-age residual in cross-sectional analyses. But regular AKG showed a much smaller, statistically insignificant association, and longitudinal findings did not remain significant after multivariable correction.[5]

This is useful hypothesis-generating evidence. It is still observational.

Is calcium-AKG the same thing as AKG?

Not automatically.

Supplement studies may use calcium alpha-ketoglutarate, delayed-release formulations, arginine-AKG, ornithine-AKG, or multi-ingredient products. Results from one formulation should not be assigned wholesale to every product labeled "AKG."

For this topic, formulation identity is part of the evidence—not a packaging detail.

Has AKG been shown to extend human lifespan?

No.

There is no human trial demonstrating that AKG supplementation extends lifespan. There is also no established evidence that it prevents dementia, cardiovascular disease, cancer, or another age-related disease simply because it affects aging pathways in laboratory models.

Those outcomes need direct human evidence.

Safety and dose context

AKG is an endogenous metabolite, but endogenous does not mean that every supplemental dose or formulation is automatically harmless.

The longevity literature is too small to characterize uncommon adverse effects or multi-year use with confidence. Evidence should stay tied to the actual compound form, dose, population, and duration that were studied.

Verdict

AKG is worth following because its biology is unusually relevant to aging research and because a serious randomized human program exists.

But the clinical evidence remains very limited for longevity claims. The next result that would truly change the picture is a well-powered randomized efficacy result with prespecified outcomes and independent replication—not another uncontrolled methylation-age headline.